D. Kh. Khaibullina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
D. Kh. Khaibullina has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Yu. N. Maksimov
Kazan State Medical Academy – a branch of the Russian Medical Academy of Continuing Professional Education
17 shared publications Д. Х. Хайбуллина
Казанская государственная медицинская академия – филиал Российской медицинской академии непрерывного профессионального образования
15 shared publications- F. I. Devlikamova
Kazan State Medical Academy
9 shared publications - R. G. Esin
Kazan Federal University
4 shared publications - E. F. Rakhmatullina
Kazan State Medical Academy – a branch of the Russian Medical Academy of Continuing Professional Education
3 shared publications - Булат Эдуардович Губеев
Kazan State Medical Academy
3 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 13,p. 29-34
Nociceptive pain in patients with hypermobility spectrum disorders and the possibilities of its correction
This article examines the characteristics of musculoskeletal (nociceptive) pain in patients with joint hypermobility syndrome and connective tissue dysplasia. Structural collagen deficiency in joint hypermobility syndrome leads to excessive mobility of spinal motion segments and peripheral joints, creating conditions for chronic microtrauma leading to the development of aseptic inflammation. This clinical case presents the course of lower back pain in a patient with joint hypermobility syndrome. A distinctive feature of the disease was the consistent development of functional blocks of the pelvic and lumbar spine joints, arising from dynamic and static overloads. Pathobiomechanical changes included muscle syndromes, represented by myotonic and myofascial pain syndromes. This case also requires differential diagnosis with neuropathic and inflammatory pain. The patient’s low compliance contributed to the disease’s protracted course. Treatment was administered according to a musculoskeletal pain protocol and included NSAIDs, a muscle relaxant, and a high-dose combination of B vitamins. Pathobiomechanical disturbances were corrected using various manual therapy techniques. Diagnosis and treatment of nociceptive pain syndrome in patients with joint hypermobility syndrome and connective tissue dysplasia require a personalized approach, taking into account comorbidity. Treatment effectiveness directly depends on the combination of pharmacotherapy and non-pharmacological treatments.
- 21 September 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 13,p. 29-34
Open AccessNociceptive pain in patients with hypermobility spectrum disorders and the possibilities of its correction
This article examines the characteristics of musculoskeletal (nociceptive) pain in patients with joint hypermobility syndrome and connective tissue dysplasia. Structural collagen deficiency in joint hypermobility syndrome leads to excessive mobility of spinal motion segments and peripheral joints, creating conditions for chronic microtrauma leading to the development of aseptic inflammation. This clinical case presents the course of lower back pain in a patient with joint hypermobility syndrome. A distinctive feature of the disease was the consistent development of functional blocks of the pelvic and lumbar spine joints, arising from dynamic and static overloads. Pathobiomechanical changes included muscle syndromes, represented by myotonic and myofascial pain syndromes. This case also requires differential diagnosis with neuropathic and inflammatory pain. The patient’s low compliance contributed to the disease’s protracted course. Treatment was administered according to a musculoskeletal pain protocol and included NSAIDs, a muscle relaxant, and a high-dose combination of B vitamins. Pathobiomechanical disturbances were corrected using various manual therapy techniques. Diagnosis and treatment of nociceptive pain syndrome in patients with joint hypermobility syndrome and connective tissue dysplasia require a personalized approach, taking into account comorbidity. Treatment effectiveness directly depends on the combination of pharmacotherapy and non-pharmacological treatments.
- Open Access
- 21 September 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 13,p. 334-341
Neck pain in patients with undifferentiated connective tissue dysplasia: Diagnostic challenges
This article discusses the differential diagnosis of treatment-resistant neck pain. Traditionally, cervicalgia is considered a nonspecific musculoskeletal pain successfully treated with standard treatment (NSAIDs, muscle relaxants) for 2–4 weeks. However, in the two presented clinical cases of middle-aged patients (45 and 48 years old) with subacute, intense pain lasting 1–2 months, standard therapy proved ineffective, necessitating a revision of the diagnostic framework. This description is of interest because it demonstrates a rare cause of secondary cervicalgia–vertebrobasilar dolichoectasia–simulating nonspecific musculoskeletal pain. Key “red flags” for further investigation included: reluctance to treatment, persistent pain, dissociation between pain severity and local muscle tension, and phenotypic features of connective tissue dysplasia (positive Beighton criteria). MR angiography verified compression of the medulla oblongata and pons by a tortuous, dolichoectatic left vertebral artery. As a result, the diagnosis was revised from nonspecific to secondary pain due to neurovascular conflict, and the patient was referred to a neurosurgeon. Therefore, in cases of prolonged neck pain associated with connective tissue dysplasia that is refractory to standard therapy, vascular anomalies must be excluded to promptly adjust the management strategy for this patient population.
- 21 September 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 13,p. 334-341
Open AccessNeck pain in patients with undifferentiated connective tissue dysplasia: Diagnostic challenges
This article discusses the differential diagnosis of treatment-resistant neck pain. Traditionally, cervicalgia is considered a nonspecific musculoskeletal pain successfully treated with standard treatment (NSAIDs, muscle relaxants) for 2–4 weeks. However, in the two presented clinical cases of middle-aged patients (45 and 48 years old) with subacute, intense pain lasting 1–2 months, standard therapy proved ineffective, necessitating a revision of the diagnostic framework. This description is of interest because it demonstrates a rare cause of secondary cervicalgia–vertebrobasilar dolichoectasia–simulating nonspecific musculoskeletal pain. Key “red flags” for further investigation included: reluctance to treatment, persistent pain, dissociation between pain severity and local muscle tension, and phenotypic features of connective tissue dysplasia (positive Beighton criteria). MR angiography verified compression of the medulla oblongata and pons by a tortuous, dolichoectatic left vertebral artery. As a result, the diagnosis was revised from nonspecific to secondary pain due to neurovascular conflict, and the patient was referred to a neurosurgeon. Therefore, in cases of prolonged neck pain associated with connective tissue dysplasia that is refractory to standard therapy, vascular anomalies must be excluded to promptly adjust the management strategy for this patient population.
- 14 September 2026
- Published by Pleiades Publishing Ltd in Bulletin of the Russian Academy of Sciences: Physics
- Vol. 90 (9) , 1500-1506
Electron Paramagnetic Resonance Method: Methemoglobin in Blood of Patients with Undifferentiated Connective Tissue Dyplasia
Blood samples from patients with undifferentiated connective tissue dysplasia (UCTD) associated with back pain were analyzed using X-band EPR at temperatures ranging from 5 to 80 K. It was found that even moderate UCTD exhibits elevated methemoglobin and erythrocyte catalase concentrations. In severe UCTD, high methemoglobin concentrations and low transferrin levels are detected in the blood. As a result of computer modeling, it was established that the EPR spectra of blood samples from patients with UCTD and volunteers (control) are described by the same set of parameters, differing mainly only in the intensities of the components.
- 14 September 2026
- Published by Pleiades Publishing Ltd in Bulletin of the Russian Academy of Sciences: Physics
- Vol. 90 (9) , 1500-1506
Electron Paramagnetic Resonance Method: Methemoglobin in Blood of Patients with Undifferentiated Connective Tissue Dyplasia
Blood samples from patients with undifferentiated connective tissue dysplasia (UCTD) associated with back pain were analyzed using X-band EPR at temperatures ranging from 5 to 80 K. It was found that even moderate UCTD exhibits elevated methemoglobin and erythrocyte catalase concentrations. In severe UCTD, high methemoglobin concentrations and low transferrin levels are detected in the blood. As a result of computer modeling, it was established that the EPR spectra of blood samples from patients with UCTD and volunteers (control) are described by the same set of parameters, differing mainly only in the intensities of the components.
- Open Access
- 19 April 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 3,p. 65-74
Mild cognitive impairment: A case study
Cognitive impairment can develop in various neurological, psychiatric, and somatic diseases and encompass a spectrum of neuropsychological changes from mild cognitive impairment to dementia. The clinical picture is determined by the underlying disease causing the cognitive impairment and its severity, manifesting as a deterioration in cognitive functions (attention, memory, speech, praxis, gnosis, and executive functions) compared to baseline. Examination of patients with cognitive impairment includes collecting complaints and anamnesis, a physical examination with neurological status, a neuropsychological examination with an assessment of cognitive functions, neuroimaging, laboratory, and instrumental diagnostic methods. The most common differential diagnoses include asthenic syndrome (chronic fatigue syndrome), anxiety and depressive disorders, fatigue syndrome after a viral illness, and chronic cerebral ischemia. To illustrate the diagnostic process, this article presents three clinical cases. The combination drug Vinpotropile has demonstrated efficacy and safety in achieving this goal. Treatment of mild cognitive impairment should be aimed at both reducing their severity and preventing the potential development of dementia. Non-pharmacological treatments play a significant role in therapy.
- 19 April 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 3,p. 65-74
Open AccessMild cognitive impairment: A case study
Cognitive impairment can develop in various neurological, psychiatric, and somatic diseases and encompass a spectrum of neuropsychological changes from mild cognitive impairment to dementia. The clinical picture is determined by the underlying disease causing the cognitive impairment and its severity, manifesting as a deterioration in cognitive functions (attention, memory, speech, praxis, gnosis, and executive functions) compared to baseline. Examination of patients with cognitive impairment includes collecting complaints and anamnesis, a physical examination with neurological status, a neuropsychological examination with an assessment of cognitive functions, neuroimaging, laboratory, and instrumental diagnostic methods. The most common differential diagnoses include asthenic syndrome (chronic fatigue syndrome), anxiety and depressive disorders, fatigue syndrome after a viral illness, and chronic cerebral ischemia. To illustrate the diagnostic process, this article presents three clinical cases. The combination drug Vinpotropile has demonstrated efficacy and safety in achieving this goal. Treatment of mild cognitive impairment should be aimed at both reducing their severity and preventing the potential development of dementia. Non-pharmacological treatments play a significant role in therapy.
- 22 January 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 23,p. 40-45
Clinical possibilities of dipyridamole in neurological practice
Cerebrovascular disease (CVD) and its chronic forms are among the most common pathologies in neurological and general medical practice. The high frequency of comorbid conditions and diseases, particularly hypertension, diabetes, lipid metabolism disorders, metabolic syndrome, and others, which contribute to the development of chronic cerebral ischemia (CCI), increases the risk of stroke and dementia – threatening, disabling complications, making chronic cerebral ischemia a pressing medical and social problem. Despite the variety of subjective symptoms of CI, cognitive impairment is considered an early and reliable manifestation of the disease. In clinical practice, one disease often masks another, misdiagnosis, and sometimes overdiagnosis contribute to the loss of valuable time and the chronicity of the disease. Timely diagnosis and adequate pathogenetic therapy aimed at improving cerebral microcirculation, optimizing neuronal metabolism, and providing neuroprotection reduce the risk of developing major complications of cerebrovascular diseases and improve the quality of life of both patients and their families. Treatment for patients with CCI includes correcting stroke risk factors, normalizing blood pressure, lowering blood cholesterol levels, and administering antithrombotic and cognitive-promoting medications. According to research data, dipyridamole, which has antiplatelet, vasotropic, antioxidant, and anti-inflammatory effects, has been used successfully in CCI. With dipyridamole use, patients with CCI experience a regression in the severity of neuropsychiatric disorders and an improvement in overall well-being, as confirmed by the presented clinical case. Non-pharmacological methods for maintaining and improving cognitive function are also of great importance.
- 22 January 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 23,p. 40-45
Clinical possibilities of dipyridamole in neurological practice
Cerebrovascular disease (CVD) and its chronic forms are among the most common pathologies in neurological and general medical practice. The high frequency of comorbid conditions and diseases, particularly hypertension, diabetes, lipid metabolism disorders, metabolic syndrome, and others, which contribute to the development of chronic cerebral ischemia (CCI), increases the risk of stroke and dementia – threatening, disabling complications, making chronic cerebral ischemia a pressing medical and social problem. Despite the variety of subjective symptoms of CI, cognitive impairment is considered an early and reliable manifestation of the disease. In clinical practice, one disease often masks another, misdiagnosis, and sometimes overdiagnosis contribute to the loss of valuable time and the chronicity of the disease. Timely diagnosis and adequate pathogenetic therapy aimed at improving cerebral microcirculation, optimizing neuronal metabolism, and providing neuroprotection reduce the risk of developing major complications of cerebrovascular diseases and improve the quality of life of both patients and their families. Treatment for patients with CCI includes correcting stroke risk factors, normalizing blood pressure, lowering blood cholesterol levels, and administering antithrombotic and cognitive-promoting medications. According to research data, dipyridamole, which has antiplatelet, vasotropic, antioxidant, and anti-inflammatory effects, has been used successfully in CCI. With dipyridamole use, patients with CCI experience a regression in the severity of neuropsychiatric disorders and an improvement in overall well-being, as confirmed by the presented clinical case. Non-pharmacological methods for maintaining and improving cognitive function are also of great importance.
- Open Access
- 24 June 2025
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 17 (3) , 49-59
Tension-type headache and effective pain relief: results of the prospective multicenter RAPID clinical trial
Pharmacological treatment of tension-type headache (TTH) attacks involves the selection of the most effective and safe analgesic. However, the choice of medication is limited by the insufficient number of evidence-based studies for this type of headache (HA).Objective: to evaluate the efficacy, safety, and tolerability of fast-release lornoxicam (Xefocam rapid) compared to standard lornoxicam (Xefocam), naproxen, and ibuprofen in relieving headache episodes in patients with frequent episodic TTH in routine clinical practice.Material and methods. The multicenter, observational (non-interventional), prospective RAPID study was conducted in 10 clinical centers across the Russian Federation and included 400 adult patients (74.5% women, 25.5% men) aged 18 to 76 years (mean age: 39.83±12.58 years) with frequent episodic TTH who were prescribed one of the following NSAIDs in routine practice: Xefocam, Xefocam rapid, ibuprofen, or naproxen. The following outcomes were assessed: the number of completely relieved TTH episodes, changes from baseline in the mean number of headache days, mean number of TTH episodes per month, mean duration of TTH episodes, and mean pain intensity on a numerical rating scale, time from drug intake to partial and complete relief of a TTH episode, mean number of days with intake of the drugs in question, number of patients using NSAIDs ≥15 days per month, number of patients taking additional medications for TTH relief, patient satisfaction with the prescribed treatment, number of patients who discontinued treatment, and the frequency of adverse events during therapy.Results. The study demonstrated overall high efficacy of Xefocam and Xefocam rapid in relieving TTH attacks. At the same time, the data obtained allow the identification of some priority effects of investigated drugs. Thus, Xefocam and Xefocam rapid showed the highest efficacy in achieving complete headache relief within 2 hours after intake. Moreover, Xefocam rapid was the most effective across all groups in achieving complete headache relief within the first 30 minutes. The greatest reduction in the numerical rating scale (NRS) score was also observed in the Xefocam rapid and Xefocam groups. In addition, Xefocam and Xefocam use demonstrated the lowest need for additional medications for pain relief among all groups, which may be related to the rapid onset of analgesic action and high safety profile of these drugs. Patients in the Xefocam rapid group more frequently rated their satisfaction with the therapy as excellent.Conclusion. Xefocam rapid showed a high safety profile and excellent tolerability, with the lowest incidence of adverse events among all study groups.
- 24 June 2025
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 17 (3) , 49-59
Open AccessTension-type headache and effective pain relief: results of the prospective multicenter RAPID clinical trial
Pharmacological treatment of tension-type headache (TTH) attacks involves the selection of the most effective and safe analgesic. However, the choice of medication is limited by the insufficient number of evidence-based studies for this type of headache (HA).Objective: to evaluate the efficacy, safety, and tolerability of fast-release lornoxicam (Xefocam rapid) compared to standard lornoxicam (Xefocam), naproxen, and ibuprofen in relieving headache episodes in patients with frequent episodic TTH in routine clinical practice.Material and methods. The multicenter, observational (non-interventional), prospective RAPID study was conducted in 10 clinical centers across the Russian Federation and included 400 adult patients (74.5% women, 25.5% men) aged 18 to 76 years (mean age: 39.83±12.58 years) with frequent episodic TTH who were prescribed one of the following NSAIDs in routine practice: Xefocam, Xefocam rapid, ibuprofen, or naproxen. The following outcomes were assessed: the number of completely relieved TTH episodes, changes from baseline in the mean number of headache days, mean number of TTH episodes per month, mean duration of TTH episodes, and mean pain intensity on a numerical rating scale, time from drug intake to partial and complete relief of a TTH episode, mean number of days with intake of the drugs in question, number of patients using NSAIDs ≥15 days per month, number of patients taking additional medications for TTH relief, patient satisfaction with the prescribed treatment, number of patients who discontinued treatment, and the frequency of adverse events during therapy.Results. The study demonstrated overall high efficacy of Xefocam and Xefocam rapid in relieving TTH attacks. At the same time, the data obtained allow the identification of some priority effects of investigated drugs. Thus, Xefocam and Xefocam rapid showed the highest efficacy in achieving complete headache relief within 2 hours after intake. Moreover, Xefocam rapid was the most effective across all groups in achieving complete headache relief within the first 30 minutes. The greatest reduction in the numerical rating scale (NRS) score was also observed in the Xefocam rapid and Xefocam groups. In addition, Xefocam and Xefocam use demonstrated the lowest need for additional medications for pain relief among all groups, which may be related to the rapid onset of analgesic action and high safety profile of these drugs. Patients in the Xefocam rapid group more frequently rated their satisfaction with the therapy as excellent.Conclusion. Xefocam rapid showed a high safety profile and excellent tolerability, with the lowest incidence of adverse events among all study groups.
- Open Access
- 4 May 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 5,p. 24-29
“I’m dizzy”: How to help a patient with dizziness effectively and quickly
One of the most common reasons for seeking medical help from doctors of various specialties is a disturbance of balance function, described by patients as dizziness. Despite the apparent simplicity and unambiguity of the complaint, it turns out that under this term patients mean completely different conditions: instability, unsteadiness when walking, swaying, nausea, pre-fainting condition, “fog in the head”, impaired coordination, etc. Often, the patient not only finds it difficult to independently describe his feelings, but also simultaneously lists several descriptors. It is not always possible to specify the patient’s desires, which complicates the diagnosis of dizziness and the establishment of the etiological factor. In connection with the above, an algorithm is currently used in the diagnosis of dizziness, which includes an assessment of the vestibular syndrome by the nature of the course (acute, episodic, chronic), identification of provoking factors (triggers), concomitant symptoms, supplemented by a physical examination, and, if necessary, paraclinical methods. In the treatment of dizziness, priority is given to its rapid and effective relief. For this purpose, drugs are used – vestibular suppressants. Given the high prevalence of comorbid conditions requiring the simultaneous use of several drugs, combination drugs have an advantage. A combination of cinnarizine and dimenhydrinate has demonstrated high efficiency and safety as a symptomatic therapy for dizziness of various origins. The combination of drug therapy with vestibular rehabilitation methods allows achieving better results and longer remission even in chronic cases of dizziness.
- 4 May 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 5,p. 24-29
Open Access“I’m dizzy”: How to help a patient with dizziness effectively and quickly
One of the most common reasons for seeking medical help from doctors of various specialties is a disturbance of balance function, described by patients as dizziness. Despite the apparent simplicity and unambiguity of the complaint, it turns out that under this term patients mean completely different conditions: instability, unsteadiness when walking, swaying, nausea, pre-fainting condition, “fog in the head”, impaired coordination, etc. Often, the patient not only finds it difficult to independently describe his feelings, but also simultaneously lists several descriptors. It is not always possible to specify the patient’s desires, which complicates the diagnosis of dizziness and the establishment of the etiological factor. In connection with the above, an algorithm is currently used in the diagnosis of dizziness, which includes an assessment of the vestibular syndrome by the nature of the course (acute, episodic, chronic), identification of provoking factors (triggers), concomitant symptoms, supplemented by a physical examination, and, if necessary, paraclinical methods. In the treatment of dizziness, priority is given to its rapid and effective relief. For this purpose, drugs are used – vestibular suppressants. Given the high prevalence of comorbid conditions requiring the simultaneous use of several drugs, combination drugs have an advantage. A combination of cinnarizine and dimenhydrinate has demonstrated high efficiency and safety as a symptomatic therapy for dizziness of various origins. The combination of drug therapy with vestibular rehabilitation methods allows achieving better results and longer remission even in chronic cases of dizziness.
- Open Access
- 12 April 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 3,p. 71-80
Diagnosis and therapy of cognitive impairment in chronic cerebral ischemia
Chronic cerebral ischemia is a common condition associated with progressive brain damage that manifests itself in various neurological disorders, including cognitive impairment. One of the etiologic factors of vascular disorders is arterial hypertension. The article discusses types of cognitive impairment and pathogenetic mechanisms of their formation. The role of the glymphatic system of the brain, the role of neuroinflammation in the implementation of cognitive impairment are discussed. The described clinical case shows the need to supplement basic therapy in patients with hypertension with drugs of other groups, in particular pentoxifylline, to improve the effectiveness of therapy. The article reviews the latest clinical and experimental studies of pentoxifylline, which show its positive effect on inflammation, endothelial dysfunction and, as a result, improvement of cognitive functions. The neuroprotective effect of pentoxifylline, which has been confirmed in experimental and clinical studies, is discussed. The possibility of using pentoxifylline in patients with mood disorders, major depressive disorder, bipolar disorder as an adjunct to the main therapy, and in cognitive impairment as monotherapy is discussed.
- 12 April 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 3,p. 71-80
Open AccessDiagnosis and therapy of cognitive impairment in chronic cerebral ischemia
Chronic cerebral ischemia is a common condition associated with progressive brain damage that manifests itself in various neurological disorders, including cognitive impairment. One of the etiologic factors of vascular disorders is arterial hypertension. The article discusses types of cognitive impairment and pathogenetic mechanisms of their formation. The role of the glymphatic system of the brain, the role of neuroinflammation in the implementation of cognitive impairment are discussed. The described clinical case shows the need to supplement basic therapy in patients with hypertension with drugs of other groups, in particular pentoxifylline, to improve the effectiveness of therapy. The article reviews the latest clinical and experimental studies of pentoxifylline, which show its positive effect on inflammation, endothelial dysfunction and, as a result, improvement of cognitive functions. The neuroprotective effect of pentoxifylline, which has been confirmed in experimental and clinical studies, is discussed. The possibility of using pentoxifylline in patients with mood disorders, major depressive disorder, bipolar disorder as an adjunct to the main therapy, and in cognitive impairment as monotherapy is discussed.
- Open Access
- 10 May 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 5,p. 70-81
Modern view on the use of alpha lipoic acid in neurological practice
Alpha lipoic acid (ALA) is an essential cofactor for mitochondrial enzymes, a powerful antioxidant, and an important component of many metabolic processes. Most research on ALA has focused specifically on its antioxidant properties. A number of conditions – aging, atherosclerosis, liver cirrhosis, diabetes mellitus, various types of polyneuropathy, psoriasis and others can significantly reduce the level of ALA in the body. The article analyzes modern literature (107 sources, including 17 systematic reviews and meta-analyses). Traditionally, ALA is used in complex therapy of patients suffering from diabetic and alcoholic polyneuropathy. However, the analysis of studies conducted around the world is not limited to these two nosological forms. The use of ALA as adjuvant therapy for a number of conditions and diseases is justified, as confirmed by clinical studies, systematic reviews and meta-analyses. All studies assessed not only the effectiveness of ALC, but also its safety and the incidence of adverse events and showed that ALC has a high safety profile. ALA has not only a pronounced antioxidant effect, but also the ability to chelate toxic metals, increase intracellular glutathione levels, reduce blood glucose levels, overcome insulin resistance, participate in mitochondrial metabolism, stimulate the production of cAMP, normalize the lipid profile, reduce the level of inflammatory markers, etc. Based on Because of the positive effect of using ALC in the treatment of various symptoms and nosologies, the list of indications requires revision, expansion and addition.
- 10 May 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 5,p. 70-81
Open AccessModern view on the use of alpha lipoic acid in neurological practice
Alpha lipoic acid (ALA) is an essential cofactor for mitochondrial enzymes, a powerful antioxidant, and an important component of many metabolic processes. Most research on ALA has focused specifically on its antioxidant properties. A number of conditions – aging, atherosclerosis, liver cirrhosis, diabetes mellitus, various types of polyneuropathy, psoriasis and others can significantly reduce the level of ALA in the body. The article analyzes modern literature (107 sources, including 17 systematic reviews and meta-analyses). Traditionally, ALA is used in complex therapy of patients suffering from diabetic and alcoholic polyneuropathy. However, the analysis of studies conducted around the world is not limited to these two nosological forms. The use of ALA as adjuvant therapy for a number of conditions and diseases is justified, as confirmed by clinical studies, systematic reviews and meta-analyses. All studies assessed not only the effectiveness of ALC, but also its safety and the incidence of adverse events and showed that ALC has a high safety profile. ALA has not only a pronounced antioxidant effect, but also the ability to chelate toxic metals, increase intracellular glutathione levels, reduce blood glucose levels, overcome insulin resistance, participate in mitochondrial metabolism, stimulate the production of cAMP, normalize the lipid profile, reduce the level of inflammatory markers, etc. Based on Because of the positive effect of using ALC in the treatment of various symptoms and nosologies, the list of indications requires revision, expansion and addition.
- 11 March 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (2) , 91-96
Effectiveness of Anvifen in the treatment of insomnia in elderly patients
OBJECTIVE Purpose of the study to determine the effectiveness of Anvifen in the case of insomnia and meteosensitivity as comorbid stress-induced disorders. MATERIAL AND METHODS 67 patients aged 60—70 years were examined, who were randomly divided into two groups: group 1 — 33 patients (20 men, 13 women), group 2 — 34 patients (19 men, 15 women). The average age of group 1 was 62.7 [61; 65] years, group 2 was 63.1 [60; 66] years (p=0.28). Research methods: questionnaire for scoring subjective characteristics of sleep, assessing the influence of meteosensitivity on daily activity using a numerical rank scale (NRS) for the previous three months. Patients in group 1 took Anvifen 250 mg (capsules) in the morning and afternoon, 500 mg (2 capsules) in the evening at 10 p.m., and upon awakening at night — an additional 250 mg of the drug per capsule. Patients in group 2 took Anvifen powder (extracting it from the capsule) 250 mg in the morning and afternoon, 500 mg in the evening at 10 p.m., and upon awakening at night — an additional 250 mg of the drug. The time from the nightly intake of Anvifen to the onset of sleep was also assessed on a three-degree scale: «fast», «long», «very long». The duration of treatment was 4 weeks. RESULTS Baseline results of measured parameters did not differ significantly between groups. After completion of treatment, the total score of subjective sleep characteristics improved in 1st (p=0.00001) and 2nd (p=0.000001) groups. Significant differences from group 1 for the better in group 2 were in «quality of sleep» (p=0.00027) and «quality of awakening» (p=0.00001). Weather sensitivity decreased in 1st (p=0.00001) and 2nd (p=0.000001) groups. CONCLUSION Anvifen showed good effectiveness in the treatment of two comorbid conditions of elderly people — insomnia and meteosensitivity. Using the drug in powder form allows you to get a faster and better effect without side-effects.
- 11 March 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (2) , 91-96
Effectiveness of Anvifen in the treatment of insomnia in elderly patients
OBJECTIVE Purpose of the study to determine the effectiveness of Anvifen in the case of insomnia and meteosensitivity as comorbid stress-induced disorders. MATERIAL AND METHODS 67 patients aged 60—70 years were examined, who were randomly divided into two groups: group 1 — 33 patients (20 men, 13 women), group 2 — 34 patients (19 men, 15 women). The average age of group 1 was 62.7 [61; 65] years, group 2 was 63.1 [60; 66] years (p=0.28). Research methods: questionnaire for scoring subjective characteristics of sleep, assessing the influence of meteosensitivity on daily activity using a numerical rank scale (NRS) for the previous three months. Patients in group 1 took Anvifen 250 mg (capsules) in the morning and afternoon, 500 mg (2 capsules) in the evening at 10 p.m., and upon awakening at night — an additional 250 mg of the drug per capsule. Patients in group 2 took Anvifen powder (extracting it from the capsule) 250 mg in the morning and afternoon, 500 mg in the evening at 10 p.m., and upon awakening at night — an additional 250 mg of the drug. The time from the nightly intake of Anvifen to the onset of sleep was also assessed on a three-degree scale: «fast», «long», «very long». The duration of treatment was 4 weeks. RESULTS Baseline results of measured parameters did not differ significantly between groups. After completion of treatment, the total score of subjective sleep characteristics improved in 1st (p=0.00001) and 2nd (p=0.000001) groups. Significant differences from group 1 for the better in group 2 were in «quality of sleep» (p=0.00027) and «quality of awakening» (p=0.00001). Weather sensitivity decreased in 1st (p=0.00001) and 2nd (p=0.000001) groups. CONCLUSION Anvifen showed good effectiveness in the treatment of two comorbid conditions of elderly people — insomnia and meteosensitivity. Using the drug in powder form allows you to get a faster and better effect without side-effects.